Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03032406 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Jan 1, 2026 to Jan 1, 2027v14
  2. Completion date: May 23, 2025 to Jan 1, 2026v13
  3. Results first posted: Mar 5, 2025 Enrollment target: 60 to 53 · Study arms: 4 to 3v12 Show 2 more changesShow less
    • Enrollment target: 60 to 53
    • Study arms: 4 to 3
  4. Primary endpoint revisedv11 See this version in full on ClinicalTrials.gov ↗
  5. Primary endpoint revised Enrollment target: 54 to 60v10 Show 1 more changeShow less
    • Enrollment target: 54 to 60

    See this version in full on ClinicalTrials.gov ↗

Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 60 to confirmed 54 · Site details revisedv8 Show 2 more changesShow less
    • Enrollment target: estimated 60 to confirmed 54
    • Site details revised
  3. Primary completion date changed from estimate of Jan 23, 2022 to May 17, 2022 Completion date: Jan 23, 2023 to May 23, 2025v7 Show 1 more changeShow less
    • Completion date: Jan 23, 2023 to May 23, 2025
  4. Re-verified, no change to tracked fieldsv6
  5. Trial status: Active, Not Recruiting to Recruiting Site details revisedv5 Show 1 more changeShow less
    • Site details revised
  6. Trial status: Recruiting to Active, Not Recruiting Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  7. Re-verified, no change to tracked fieldsv3
  8. Completion date: Jan 23, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.
Trial Details
NCT Number NCT03032406
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Breast Cancer Stage IIB
Enrollment 53 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov